Narwhal Capital Management Has $8.92 Million Stock Holdings in Abbott Laboratories $ABT

Key Points

• Narwhal Capital Management increased its stake in Abbott Laboratories by 9.2%, owning 65,569 shares valued at approximately $8.92 million as of the end of the last quarter.
• Abbott's recent earnings report showed earnings per share of $1.26, matching analysts' expectations, with a net margin of 32.43% and revenue of $11.14 billion, exceeding forecasts.
• The company declared a quarterly dividend of $0.59, resulting in an annualized yield of 1.8% and a payout ratio of 29.57%.

Narwhal Capital Management boosted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 9.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,569 shares of the healthcare product maker's stock after buying an additional 5,514 shares during the quarter. Narwhal Capital Management's holdings in Abbott Laboratories were worth $8,918,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Hughes Financial Services LLC acquired a new position in Abbott Laboratories during the first quarter worth $27,000. Abound Financial LLC acquired a new position in Abbott Laboratories during the first quarter worth $28,000. Elequin Capital LP acquired a new position in Abbott Laboratories during the first quarter worth $30,000. JCIC Asset Management Inc. acquired a new position in Abbott Laboratories during the first quarter worth $32,000. Finally, Vision Financial Markets LLC acquired a new position in Abbott Laboratories during the first quarter worth $33,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Stock Up 1.1%

NYSE ABT opened at $134.45 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The firm has a 50-day simple moving average of $132.30 and a 200 day simple moving average of $131.48. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The stock has a market cap of $234.00 billion, a PE ratio of 16.85, a PEG ratio of 2.52 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. During the same quarter last year, the company earned $1.14 earnings per share. The firm's revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio is 29.57%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ABT shares. The Goldman Sachs Group increased their target price on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a "buy" rating in a research report on Wednesday, October 1st. William Blair upgraded shares of Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Mizuho upped their price target on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, July 16th. Weiss Ratings restated a "buy (b)" rating on shares of Abbott Laboratories in a report on Wednesday. Finally, Evercore ISI upped their price target on shares of Abbott Laboratories from $140.00 to $144.00 and gave the company an "outperform" rating in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, Abbott Laboratories presently has a consensus rating of "Moderate Buy" and an average price target of $146.24.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.